Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday.

The Trump administration’s new TrumpRx deal with Eli Lilly and Novo Nordisk will slash GLP-1 drug prices, including Ozempic, Wegovy, and Zepbound, to as low as $245 per dose for Medicare, Medicaid, and direct consumers.

Even after Trump’s new deal, obesity drugs are still too expensive.

President Donald Trump announced that his administration has finally struck a deal with Novo Nordisk and Eli Lilly to reduce the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. Currently,

The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.